2 unknown, 1 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 2, Completed 1 |
Follow Fluzoparib+Apatinib: new trials by email Literature Review of Fluzoparib+Apatinib trials Research Report on Fluzoparib+Apatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi Fluzoparib, Fluzoparib+Apatinib - Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary | Phase 2 | Unknown | Guangxi Medical University | 80 | 2023-12-10 | 2023-12-07 |
| Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment Fluzoparib+Apatinib, Fluzoparib Monotherapy - Relapsed Ovarian Cancer | Phase 2 | Unknown | Xiaohua Wu MD | 132 | 2022-08-01 | 2022-07-29 |
| A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients Fluzoparib+Apatinib, Fluzoparib - Relapsed Ovarian Cancer | Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 100 | 2020-10-16 | 2025-02-24 |
Ovarian Neoplasms (3) · Fallopian Tube Neoplasms (1)
Guangxi Medical University (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Xiaohua Wu MD (1)
China (2)